Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For people with Mycosis Fungoides (MF) or Sézary Syndrome (SS):
- A confirmed diagnosis of mycosis fungoides or Sézary syndrome at the enrolling hospital, with disease at stage IB or higher (meaning patches, plaques, or papules covering at least 10% of the skin, or affecting internal organs)
- People whose mycosis fungoides tests negative for the CD30 marker are still eligible
- Adults aged 18 or older
- People with a general health and activity level rated as reasonably functional (an ECOG performance score of 2 or below — confirm with trial site)
- For Group 1 (Cohort 1): People who have never previously received the drug brentuximab vedotin
- For Group 2 (Cohort 2): People who have previously received brentuximab vedotin for MF or SS (note: people who left Cohort 1 due to side effects are not eligible for Cohort 2)
- Any previous cancer treatments must have been stopped at least 2 weeks before starting the trial
- Low-dose steroid use (equivalent to no more than 10mg per day of prednisone) may be permitted in certain circumstances, after discussion with the lead doctor
- People who are HIV-positive may be eligible if they have been on stable HIV treatment for at least 12 weeks before the trial starts, and have a CD4 cell count above 200 within 7 days of starting
- Women who could become pregnant must be using an acceptable form of contraception as required by the institution
For people with Lymphomatoid Papulosis (LyP):
- A confirmed diagnosis of lymphomatoid papulosis at the enrolling hospital
- A condition that the treating doctor judges requires systemic (whole-body) treatment
- Adults aged 18 or older
- People with a general health and activity level rated as reasonably functional (ECOG performance score of 2 or below — confirm with trial site)
- Any previous cancer treatments must have been stopped at least 2 weeks before starting the trial
- Low-dose steroid use may be permitted in certain circumstances (same conditions as above)
- People who are HIV-positive may be eligible under the same conditions described above
- Women who could become pregnant must be using an acceptable form of contraception as required by the institution
Who may not be able to join:
- People currently receiving other systemic (whole-body) cancer treatments for MF, SS, or LyP at the same time as this trial
- People with moderate or severe nerve damage or nerve-related symptoms (Grade 2 or higher neuropathy — confirm with trial site)
- People with severely reduced kidney function (confirm with trial site)
- People with moderate or severe liver disease (confirm with trial site)
- Women who could become pregnant must have a negative blood pregnancy test within one week of starting the trial
- For Cohort 1 only: People who have previously received the drug brentuximab vedotin
- People currently receiving systemic treatment for a separate, different cancer (other than T-cell lymphoma) — though some exceptions may be possible after discussion with the principal investigator
- For Cohort 2 only: People whose MF or SS got worse while on the standard dose of brentuximab vedotin previously
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Alison Moskowitz, MD, Memorial Sloan Kettering Cancer Center
Phone: 646-608-3726
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
overall response
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.